Luye Pharma Group (HKSE:02186) EBIT per Share : HK$0.40 (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Luye Pharma Group EBIT per Share?

Luye Pharma Group's EBIT per Share for the six months ended in Dec. 2023 was HK$0.24. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.40.

During the past 12 months, the average EBIT per Share Growth Rate of Luye Pharma Group was -1.30% per year. During the past 3 years, the average EBIT per Share Growth Rate was -12.50% per year. During the past 5 years, the average EBIT per Share Growth Rate was -16.70% per year. During the past 10 years, the average EBIT per Share Growth Rate was -7.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Luye Pharma Group's EBIT per Share or its related term are showing as below:

HKSE:02186' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -42.6 Med: 1.2 Max: 42.7
Current: -12.5

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Luye Pharma Group was 42.70% per year. The lowest was -42.60% per year. And the median was 1.20% per year.

HKSE:02186's 3-Year EBIT Growth Rate is ranked worse than
78.02% of 860 companies
in the Drug Manufacturers industry
Industry Median: 7.45 vs HKSE:02186: -12.50

Luye Pharma Group's EBIT for the six months ended in Dec. 2023 was HK$918 Mil.

Luye Pharma Group EBIT per Share Historical Data

The historical data trend for Luye Pharma Group's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luye Pharma Group EBIT per Share Chart

Luye Pharma Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

0.67

0.51

0.12

0.37

0.40

Luye Pharma Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-0.13	0.20	0.18	0.16	0.24

Luye Pharma Group EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Luye Pharma Group's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	1504.552	/	3728.363
=	0.40

Luye Pharma Group's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	918.478	/	3762.223
=	0.24

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.40

Luye Pharma Group (HKSE:02186) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Luye Pharma Group EBIT per Share Related Terms

Thank you for viewing the detailed overview of Luye Pharma Group's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Luye Pharma Group (HKSE:02186) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Luye Pharma Group Ltd (HKSE:02186) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

LYPHF:USA LUP:Germany LUP:Germany

Address

No. 15 Chuang Ye Road, High-tech Industrial Development Zone, Shandong, Yantai, CHN, 264003

Website

https://www.luye.cn

Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on developing, producing, and selling pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for global use in Asia, Europe, and the United States.

Executives

Ubs Group Ag	2201 Interest of corporation controlled by you
Liu Dianbo	2301 Trustee
Luye Life Sciences Group Ltd	2201 Interest of corporation controlled by you
Luye Pharma Holdings Ltd.	2201 Interest of corporation controlled by you
Nelumbo Investments Limited	2201 Interest of corporation controlled by you
Shorea Lbg	2201 Interest of corporation controlled by you
Luye Pharmaceutical Investment Co., Ltd.	2101 Beneficial owner
Ginkgo (ptc) Limited	2301 Trustee
Luye Pharmaceutical International Co., Ltd.	2201 Interest of corporation controlled by you
Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Hillhouse Nev Holdings Limited	2101 Beneficial owner
Hillhouse Investment Management, Ltd.	2102 Investment manager
Hillhouse Fund V, L.p.	2201 Interest of corporation controlled by you
Xin Ye Sheng Wu Yi Yao Kong Gu You Xian Gong Si
Yang Yu Fen

Luye Pharma Group (HKSE:02186) Headlines

No Headlines